The versatile Xoft® Axxent® Electronic Brachytherapy (eBx®) System® utilizes breakthrough electronic brachytherapy technology to provide expanded treatment options for a range of cancers. With the Xoft System, highly focused therapeutic radiation of the disease target is possible in a minimally shielded setting, while sparing surrounding healthy tissue.
The Xoft System is FDA cleared, CE marked, and licensed in a growing number of countries for the treatment of cancer anywhere in the body, including early-stage breast cancer, non-melanoma skin cancer (NMSC), and gynecological cancers. Indications currently under investigation include prostate, pancreatic, colorectal and brain cancers. Our commitment to this innovative technology is driven by the valuable benefits it offers to physicians, facilities, and patients.
Unfortunately, it is NOT legal unless the manufacturers have branches with qualification in China to deal with the registration issues. Otherwise, it is a must-do that manufacturers overseas are required to appoint a Chinese agent for the medical device registration.
Regarding the registration fee for NMPA, as for the imported medical devices, the registration of Class II medical device needs 210,900 CNY while that of Class III costs 308,800 CNY. In addition, other kinds of possible fees should be taken into consideration such as fees of document translation, clinical trial, and so forth.
After the registration materials are accepted by NMPA, technical review for Class II medical devices takes 60 working days to process while for Class III medical devices, technical review takes 90 working days. If supplementary materials are required by NMPA, manufacturers are obliged to conduct submission within one year, otherwise the review may result in termination.
MDs with CE or FDA certificate are feasible to enter SAR without NMPA certificate. As for the Greater Bay Area and Hainan province, MDs marketed in HK or MO as a premise can enter the pilot areas if designated medical institutions in pilot areas are willing to procure medical devices out of clinical urgent needs under the approval of local government.
Copyright © Chindex Medical Limited
